Pancreatic Cancer Research

ResearcherUniversity of California San DiegoActive in the last 2 years

Stephen Philip Schoenberger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9870-7340; OpenAlex author ID A5014729402; NIH RePORTER profile ID 2264506. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
1
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 grant

Papers 2

  1. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metasta… Co-author DOI 10.1136/jitc-2022-006133↗
  2. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Co-author DOI 10.1158/2326-6066.cir-19-0101↗

Grants 1

  1. Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer R01CA282439↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rebekah Ruth White · 2 shared papers, 1 shared grant, 2019–2026 · strength 1.52
  2. Partha Ray · 2 shared papers, 2019–2023 · strength 0.26
  3. Jayanth S. Shankara Narayanan · 2 shared papers, 2019–2023 · strength 0.26
  4. Suna Erdem · 1 shared paper, 2023 · strength 0.16
  5. Hervé Tiriac · 1 shared paper, 2023 · strength 0.16
  6. Diego A. Vicente · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.